Načítá se...
Do single‐arm trials have a role in drug development plans incorporating randomised trials?
Often, single‐arm trials are used in phase II to gather the first evidence of an oncological drug's efficacy, with drug activity determined through tumour response using the RECIST criterion. Provided the null hypothesis of ‘insufficient drug activity’ is rejected, the next step could be a rand...
Uloženo v:
| Vydáno v: | Pharm Stat |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4855632/ https://ncbi.nlm.nih.gov/pubmed/26609689 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pst.1726 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|